STO · ALZCUR.ST
AlzeCure Pharma AB
SEK 6.50-SEK 0.02 (-0.31%)
AlzeCure Pharma AB’s quoted price sits in the upper half of its reported 52-week range, 25.12% below the high.
Loading market information…
STO · KDEV.ST · SEK
Stock price, earnings
Quote as of Oct 29, 2026, 04:29 PM UTC. Cached market data; not a live quote.
One-year closing-price history · SEK. Historical prices are not a forecast.
KDventures AB’s quoted price sits in the lower half of its reported 52-week range, 82.14% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow KDventures AB’s reporting calendar.
THE COMPANY BEHIND THE TICKER
KDventures AB is a venture capital firm specializing in investments in growth capital, seed stage, and early stage companies. It seeks to invest in pharmaceutical research and development, medical research, medical innovations, healthcare technology, gene research and development, drug delivery technologies, biotechnology, and life science tools and service sectors. The firm seeks to invest in the Nordic region with a focus on Sweden, Iceland, Norway, Finland, and Denmark. It prefers to be a lead investor in its portfolio companies however does consider co-investments also. It seeks to invest in up to five projects annually. The company was formerly known as Karolinska Development AB (publ) and change its name to KDventures AB in February 2026. KDventures AB was founded in 2003 and is headquartered in Solna, Sweden.
Latest available per-share figures in SEK. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:55 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
SEK 6.50-SEK 0.02 (-0.31%)
AlzeCure Pharma AB’s quoted price sits in the upper half of its reported 52-week range, 25.12% below the high.
SEK 15.50-SEK 0.50 (-3.13%)
Mentice AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 18.21% below the high.
SEK 1.19+SEK 0.04 (+3.66%)
Isofol Medical AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 4.96% below the high.
SEK 3.17+SEK 0.12 (+3.93%)
Bio-Works Technologies AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 36.35% below the high.
SEK 2.12+SEK 0.07 (+3.41%)
IRLAB Therapeutics AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 23.74% below the high.
SEK 14.35+SEK 0.10 (+0.7%)
Lipum AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 28.07% below the high.
SEK 12.60-SEK 0.30 (-2.33%)
Physitrack PLC’s quoted price sits in the upper half of its reported 52-week range, 22.94% below the high.
SEK 2.09+SEK 0.04 (+1.95%)
Initiator Pharma A/S’s quoted price sits in the lower half of its reported 52-week range, 42.74% below the high.
